# reload+after+2024-01-23 04:43:18.761485
address1§Saemundargata 15-19
city§Reykjavik
zip§102
country§Iceland
phone§354 422 4500
website§https://www.alvotech.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
fullTimeEmployees§917
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robert  Wessman', 'age': 53, 'title': 'CEO, Founder & Executive Chairman', 'yearBorn': 1970, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joel  Morales', 'age': 45, 'title': 'Chief Financial Officer', 'yearBorn': 1978, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Faysal  Kalmoua', 'age': 47, 'title': 'COO & Director', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Giedrius  Zunda', 'title': 'Chief Technical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph E. McClellan', 'age': 49, 'title': 'Chief Scientific Officer', 'yearBorn': 1974, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Rose-Marie  Ohlsson', 'title': 'Chief Information Officer', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tanya  Zharov', 'age': 56, 'title': 'General Counsel', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Eva Yr Gunnlaugsdottir', 'title': 'Vice President of People & Culture', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anil  Okay', 'age': 37, 'title': 'Chief Commercial Officer', 'yearBorn': 1986, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ming  Li', 'age': 46, 'title': 'Chief Strategy Officer', 'yearBorn': 1977, 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.118
priceToSalesTrailing12Months§51.16068
currency§USD
dateShortInterest§1702598400
forwardEps§-0.5
exchange§NGM
quoteType§EQUITY
shortName§Alvotech
longName§Alvotech
firstTradeDateEpochUtc§1655386200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§abc02b5d-5044-3532-9d0d-b9db1659ed78
gmtOffSetMilliseconds§-18000000
targetHighPrice§22.0
targetLowPrice§6.0
targetMeanPrice§11.25
targetMedianPrice§10.0
recommendationMean§2.4
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§0.591
grossMargins§-1.0889701
ebitdaMargins§0.0
trailingPegRatio§None
